Application of stimulating agent CRX-675 of Toll-like receiver in resisting pulmonary fibrosis

Abstract

The invention discloses the application of Toll-like receptor 4 agonist CRX-675 in resisting pulmonary fibrosis. The inventor found through systematic research that for C57BL / 6 mice, the pulmonary fibrosis model was caused by intratracheal injection of bleomycin (3U / Kg). After 7 days of modeling, intraperitoneal injection of CRX-675 (10mg / kg / day) to the 21st day; through histopathological and biochemical detection methods, it was found that activating the TLR4 signaling pathway can significantly reduce the mortality of bleomycin-infused mice; activating the TLR4 signaling pathway can significantly reduce the lung inflammation induced by bleomycin and damage, reduce bleomycin-induced pulmonary fibrosis, including reducing lung collagen deposition, hydroxyproline content and expression of α-SMA, and improve lung function in mice with pulmonary fibrosis.

Description

technical field [0001] The invention designs a new application of Toll-like receptor 4 agonist CRX-675 in treating pulmonary fibrosis, and belongs to the technical field of medicine. Background technique [0002] Fibrosis is the main cause of disability and death in many chronic diseases, which seriously threatens people's health and life. According to relevant statistics in the United States, nearly 45% of the fatal diseases can be attributed to tissue fibroproliferative diseases. In recent years, the morbidity and mortality of pulmonary fibrosis have been on the rise. For example, after the clinical diagnosis of idiopathic pulmonary fibrosis is confirmed, the 3-year survival rate is less than 50%, and the 5-year mortality rate reaches 65%. Many chronic lung diseases, including asthma, chronic bronchitis, bronchiectasis, COPD, tuberculosis, lung cancer, interstitial lung disease, etc., are accompanied by fibrotic pathological changes. Pulmonary fibrosis can cause persist...

AI Technical Summary

Problems solved by technology

The exact pathogenesis of pulmonary fibrosis has not yet been fully elucidated

Except for pirfenidone, which has been approved for the treatment of interstitial pulmonary fibrosis in Japan (but not approved by the US FDA), there are currently no other effective drugs and treatments

Images